Successful curative resection of gallbladder cancer following S‑1 chemotherapy: A case report and review of the literature

Zhu AX, Hong TS, Hezel AF and Kooby DA: Current management of gallbladder carcinoma. Oncologist. 15:168–181. 2010.

Glimelius B, Hoffman K, Sjödén PO, et al: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 7:593–600. 1996.

Ishikawa T, Horimi T, Shima Y, et al: Evaluation of aggressive surgical treatment for advanced carcinoma of the gallbladder. J Hepatobiliary Pancreat Surg. 10:233–238. 2003.

Shirasaka T, Shimamato Y, Ohshimo H, et al: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 7:548–557. 1996.

Boku N, Yamamoto S, Fukuda H, et al: Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 10:1063–1069. 2009.

Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 9:215–221. 2008.

Ueno H, Okusaka T, Ikeda M, Takezako Y and Morizane C: Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer. 91:1769–1774. 2004.

Van Triest B, Pinedo HM, Giaccone G and Peters GJ: Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol. 2000 Apr;11(4): 385–91

Miyoshi Y, Uemura H, Ishiguro H, et al: Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer. Prostate Cancer Prostatic Dis. 8:260–265. 2005.

Diasio RB and Lu Z: Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol. 12:2239–2242. 1994.

Kuramochi H, Hayashi K, Uchida K, et al: Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res. 12:29–33. 2006.

Manfredi S, Benhamiche AM, Isambert N, et al: Trends in incidence and management of gallbladder carcinoma: a population-based study in France. Cancer. 89:757–762. 2000.

Grobmyer SR, Lieberman MD and Daly JM: Gallbladder cancer in the twentieth century: single institution’s experience. World J Surg. 28:47–49. 2004.

Kitajima K, Kobayashi S, Shiba H, et al: Successful treatment of advanced gallbladder cancer with an anticancer drug S-1: assessment based on intratumoral gene. Int J Clin Oncol. 13:545–551. 2008.

Bismuth H, Adam R, Lévi F, et al: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 224:509–520. 1996.

Alberts SR, Horvath WL, Sternfeld WC, et al: Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 23:9243–9249. 2005.

Adam R, Avisar E, Ariche A, et al: Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol. 8:347–353. 2001.

Morimoto H, Ajiki T, Takase S, et al: Resection of gallbladder cancer with hepatic metastasis after chemotherapy with gemcitabine. J Hepatobiliary Pancreat Surg. 15:655–658. 2008.

Takita M, Iwasaki E, Hatogai K, et al: Advanced gallbladder cancer that showed complete response to gemcitabine plus S-1 chemotherapy. Nihon Shokakibyo Gakkai Zasshi. 108:1263–1270. 2011.(in Japanese).

Soong R, Shah N, Salto-Tellez M, et al: Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol. 19:915–919. 2008.